SG
Shree Ganesh Remedies Ltd (SGRL)
₹605.75
Mkt cap
₹778 Cr
P/E ratio
64.20
P/B
4.70
Div yield
0.00%
ROE
10.80%
ROCE
14.20%
EPS (TTM)
₹9.44
Book value
₹129
52W range
477–750
Sector
Healthcare
Price history
Previous close
Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries. [1] [2]
NSE SGRLBSE 540737
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−19.22% from high₹606
₹477+26.98% from low₹750
Current
₹605.75
Prev close
₹616.05
Day
−1.67%
Price performance
1D
−1.75%
1W
−8.01%
1M
−7.57%
3M
+20.80%
6M
—
1Y
—
YTD
+12.80%
Financials
Revenue, profit & margin
P/E ratio
64.2×
SGRL is 98% above the sector median of 32.5×
SGRL64.2×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.42 | 27.97 | 37.33 | 24.78 | 32.33 | 27.05 | 24.43 | 24.67 | 30.32 | 21.11 | 33.20 | 14.36 | 23.29 | |
| YoY Sales growth | +57.20% | +27.19% | +26.07% | -7.26% | -3.26% | -3.29% | -34.56% | -0.44% | -6.22% | -21.96% | +35.90% | -41.79% | -23.19% | |
| Expenses | 24.19 | 19.76 | 20.39 | 16.65 | 21.02 | 17.14 | 14.55 | 17.37 | 20.70 | 14.38 | 21.82 | 11.01 | 19.35 | |
| Operating Profit | 9.23 | 8.21 | 16.94 | 8.13 | 11.31 | 9.91 | 9.88 | 7.30 | 9.62 | 6.73 | 11.38 | 3.35 | 3.94 | |
| OPM % | 27.62% | 29.35% | 45.38% | 32.81% | 34.98% | 36.64% | 40.44% | 29.59% | 31.73% | 31.88% | 34.28% | 23.33% | 16.92% | |
| Other Income | 0.80 | 1.11 | 1.32 | 0.54 | 0.19 | 0.71 | 2.29 | 0.66 | 0.69 | 0.66 | 1.02 | 0.94 | 1.41 | |
| Interest | 0.01 | 0.02 | 0.15 | 0.32 | 0.43 | 0.38 | 0.96 | 0.94 | 1.01 | 0.74 | 0.88 | 0.32 | 0.58 | |
| Depreciation | 1.41 | 1.88 | 1.86 | 2.02 | 2.42 | 2.70 | 2.42 | 2.42 | 2.59 | 2.67 | 2.80 | 2.44 | 2.50 | |
| Profit before tax | 8.61 | 7.42 | 16.25 | 6.33 | 8.65 | 7.54 | 8.79 | 4.60 | 6.71 | 3.98 | 8.72 | 1.53 | 2.27 | |
| Tax % | 23.81% | 35.31% | 22.46% | 26.70% | 25.78% | 27.85% | 24.80% | 25.00% | 26.23% | 22.36% | 28.10% | 27.45% | 27.75% | |
| Net Profit | 6.55 | 4.80 | 12.59 | 4.65 | 6.42 | 5.43 | 6.60 | 3.45 | 4.96 | 3.10 | 6.27 | 1.12 | 1.63 | |
| EPS in Rs | 5.41 | 3.97 | 10.40 | 3.62 | 5.00 | 4.23 | 5.14 | 2.69 | 3.86 | 2.41 | 4.88 | 0.87 | 1.27 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.83%Promoter
Promoters72.83%
FIIs0.00%
DIIs0.99%0.47
Public26.17%0.48
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Shree Ganesh Rem | ₹605.75 | 64.16 | 778 | 0.00% | 2 | −67.14% | 23 | −23.19% | 14.16% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports10
Concall transcripts21
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 18 Nov - Earnings conference call transcript from November 14, 2026 uploaded on company website.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 Nov - Audio recording of Shree Ganesh Remedies' earnings call held on November 14, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Nov - Shree Ganesh Remedies invites investors to Q2 and H1FY27 earnings call on 14 November 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 1 Nov - Shree Ganesh Remedies reported Q2/H1FY27 results; commenced commercial production of two intermediates and completed Block 7A.Announcement under Regulation 30 (LODR)-Investor Presentation 1 Nov






